Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference

Audio By Carbonatix

LOS ANGELES--(BUSINESS WIRE)--Feb 26, 2025--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45 th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston.

A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250226129242/en/

CONTACT: Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[email protected]

[email protected] Schull or Olipriya Das, Russo Partners, +1 212 845 4200

[email protected]

[email protected]

KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS PRACTICE MANAGEMENT BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE ONCOLOGY

SOURCE: Puma Biotechnology, Inc.

Copyright Business Wire 2025.

PUB: 02/26/2025 04:15 PM/DISC: 02/26/2025 04:16 PM

http://www.businesswire.com/news/home/20250226129242/en